Aravive To Present at The Cowen and Company 40th Annual Health Care Conference

HOUSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. ARAV, a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual Health Care Conference in Boston, MA.

Event: Cowen & Company 40th Annual Health Care Conference
Presentation Date & Time: Tuesday, March 3, 2020, 8:00 AM ET
Location: New York, NY

A live webcast of the presentation will be available at http://ir.aravive.com.

About Aravive
Aravive, Inc. ARAV is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Aravive's lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500 starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The GAS6-AXL signaling pathway also plays a significant role in fibrogenesis. Aravive is evaluating AVB-500 in platinum-resistant ovarian cancer, clear cell renal cell carcinoma (ccRCC) and kidney fibrosis and intends to expand development into additional oncology and fibrotic indications. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

Contacts:
Investors:
Christina Tartaglia
Stern Investor Relations
christina@sternir.com 

Media:
Heidi Chokeir, Ph.D.
Canale Communications
heidi@canalecomm.com